Paper42585605
Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility.
Hazan J and 3 others. Neurology, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility. Papers, record 42585605. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42585605
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Blood-Based Biomarkers for Alzheimer Disease in Primary Care: The Gap Between Biology and Clinical Utility.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| Biomarkers | Major topic |
| Humans | |
| Primary Health Care |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36745974 | A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. | EBioMedicine | 2023 | https://conductscience.org/library/papers/36745974 | PubMed |
| 2 | 34838239 | Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. | Lancet Neurol | 2022 | https://conductscience.org/library/papers/34838239 | PubMed |
| 3 | 39483064 | Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. | JAMA Neurol | 2024 | https://conductscience.org/library/papers/39483064 | PubMed |
| 4 | 39068545 | Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. | JAMA | 2024 | https://conductscience.org/library/papers/39068545 | PubMed |
| 5 | 39544104 | The Italian guideline on diagnosis and treatment of dementia and mild cognitive impairment. | Age Ageing | 2024 | https://conductscience.org/library/papers/39544104 | PubMed |
| 6 | 40729527 | Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/40729527 | PubMed |
| 7 | 38866966 | Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease. | Nat Rev Neurol | 2024 | https://conductscience.org/library/papers/38866966 | PubMed |
| 8 | 40145267 | Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/40145267 | PubMed |
| 9 | 8028470 | Ruling out or ruling in disease with the most sensitive or specific diagnostic test: short cut or wrong turn? | Med Decis Making | 1994 | https://conductscience.org/library/papers/8028470 | PubMed |
| 10 | 29710225 | Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. | JAMA Neurol | 2018 | https://conductscience.org/library/papers/29710225 | PubMed |
| 11 | 22740357 | Principles for high-quality, high-value testing. | Evid Based Med | 2013 | https://conductscience.org/library/papers/22740357 | PubMed |
| 12 | 33326253 | Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33326253 | PubMed |
| 13 | 21403122 | Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. | Circulation | 2011 | https://conductscience.org/library/papers/21403122 | PubMed |
| 14 | 40951924 | Co-pathology in Alzheimer's disease and Lewy body disease and its association with neuropsychiatric symptoms. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/40951924 | PubMed |
| 15 | 39353147 | Challenges in a Biological Definition of Alzheimer Disease. | Neurology | 2024 | https://conductscience.org/library/papers/39353147 | PubMed |
| 16 | 39044504 | Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment. | J Prev Alzheimers Dis | 2024 | https://conductscience.org/library/papers/39044504 | PubMed |
| 17 | 27683318 | Measures of Diagnostic Accuracy: Basic Definitions. | EJIFCC | 2009 | https://conductscience.org/library/papers/27683318 | PubMed |
| 18 | 35908251 | The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. | Alzheimers Dement | 2022 | https://conductscience.org/library/papers/35908251 | PubMed |
| 19 | 38252443 | Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. | JAMA Neurol | 2024 | https://conductscience.org/library/papers/38252443 | PubMed |
| 20 | 37248905 | Advancing Diagnostic Certainty in Alzheimer's Disease: A Synthesis of the Diagnostic Process. | J Alzheimers Dis | 2023 | https://conductscience.org/library/papers/37248905 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42585605
GET https://conductscience.org/api/papers/v1/42585605/references?page=2